Nomination committee for the 2024 Annual General Meeting

According to the resolution of the 2023 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of the number of votes at the end of December 2023.

At the end of December, the three largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB and SEB Fonder. All have agreed to participate in the nomination committee's work.

Prior to the 2024 Annual General Meeting, the Nomination Committee consists of Christer Fåhraeus (appointed by Fårö Capital AB), Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and Erik Hallengren (appointed by SEB Fonder).

Shareholders who wish to submit proposals to the Nomination Committee are encouraged to send an e-mail to info@eqlpharma.com.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.